Aprea Therapeutics’ (APRE) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Aprea Therapeutics (NASDAQ:APRE) in a research note issued to investors on Thursday morning, Benzinga reports. They currently have a $20.00 target price on the stock.

Separately, Wedbush reaffirmed an “outperform” rating and issued a $11.00 price target on shares of Aprea Therapeutics in a research note on Tuesday, August 13th.

Aprea Therapeutics Stock Up 4.6 %

Shares of NASDAQ:APRE opened at $4.08 on Thursday. Aprea Therapeutics has a twelve month low of $2.15 and a twelve month high of $8.85. The firm has a market capitalization of $22.15 million, a PE ratio of -1.23 and a beta of 1.03. The company has a 50-day moving average price of $3.27 and a two-hundred day moving average price of $4.07.

Aprea Therapeutics (NASDAQ:APRE) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.05. The firm had revenue of $0.56 million during the quarter, compared to analyst estimates of $0.10 million. Aprea Therapeutics had a negative return on equity of 56.38% and a negative net margin of 1,012.37%. Analysts anticipate that Aprea Therapeutics will post -2.74 earnings per share for the current fiscal year.

Insider Activity at Aprea Therapeutics

In related news, Director Marc Duey sold 6,462 shares of the business’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $4.58, for a total value of $29,595.96. Following the transaction, the director now directly owns 233,651 shares of the company’s stock, valued at approximately $1,070,121.58. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Bernd R. Seizinger bought 10,000 shares of the stock in a transaction on Friday, October 11th. The stock was acquired at an average cost of $2.68 per share, for a total transaction of $26,800.00. Following the acquisition, the director now owns 44,730 shares of the company’s stock, valued at $119,876.40. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Marc Duey sold 6,462 shares of the stock in a transaction on Friday, October 18th. The shares were sold at an average price of $4.58, for a total value of $29,595.96. Following the sale, the director now directly owns 233,651 shares in the company, valued at $1,070,121.58. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have purchased 42,290 shares of company stock worth $165,096. Corporate insiders own 12.80% of the company’s stock.

Institutional Investors Weigh In On Aprea Therapeutics

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Stonepine Capital Management LLC acquired a new position in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 137,174 shares of the company’s stock, valued at approximately $558,000. Aprea Therapeutics accounts for approximately 0.5% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 21st biggest position. Stonepine Capital Management LLC owned 2.53% of Aprea Therapeutics as of its most recent SEC filing. 34.19% of the stock is currently owned by institutional investors.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.